Background: Urolithiasis is a medical condition characterized by formation of stone which comprises of calcium oxalate, magnesium ammonium phosphate and uric acid. Reoccurrence becomes the primary hindering factor in providing relief for urolithiasis; hence there is a need of alternate therapeutic strategy that may effectively combat and halt the formation and nucleation of the crystals. Objective: The main aim of the present investigation is to explore the anti-urolithiasis potential of the two versatile siddha formulations Amukkara Chooranam (AKC) and Karisalai karpam chooranam (KKC) using diffusion gel growth technique. Materials and Methods: Silica hydrogel matrix was divided in to three groups which were control, AKC and KKC treated groups. Test drugs were screened at two dose levels of 0.5% and 1%. The efficiency of the formulations was screened by comparing the crystal size of the control and treatment medium. Results: The average size of the crystals in the control medium was found to be 2.12 ± 0.22 cm, whereas the crystal size was significantly decreased in medium contains 0.5% and 1% of AKC with the size of 1.4 ± 0.15 and 1.14 ± 0.18 cm. Similar type of findings were observed in medium consist of 0.5% and 1 % KKC with the size of 1.52 ± 0.13 and 1.08 ± 0.17 cm. Conclusion: Results clearly indicates that both the siddha formulations offers maximum percentage inhibition on the crystal growth in the tested medium, this efficacy may be due to presence of versatile phytocomponents present in the formulations.
BackgroundCOVID-19 resulted in loss of human lives owing to respiratory failure caused by dysregulated immune system. Though many treatments are evaluated, the most appropriate is yet to be established. We hypothesized accelerated recovery and reduced mortality in mild, moderate and severe COVID-19 with Siddha regimen consisting of natural products.MethodsIn a randomized, controlled open-label trial conducted on 200 hospitalized COVID-19 patients, they were allocated equally to be treated with add-on Siddha regimen with Standard care or only standard care. The primary and secondary end points were accelerated recovery (≤ 7 days) and mortality comparison between the groups respectively. Patients were followed through 90 days.ResultsIn this study the accelerated recovery was 59.0% and 27.0% in treatment and control group (ITT analyses) (p < 0.001) respectively and Odds for it were four times higher in the treatment group (OR: 3.9; 95% CI: 1.9, 8.0). The estimated median time for recovery in the treatment group was 7 days (95% CI: 6.0, 8.0; p=0.003) and 10 days (95% CI: 8.7, 11.3) in control. Hazard ratio for death in control was 2.3 times that of treatment group. No adverse reactions or alarming laboratory values were observed in response to intervention. In severe treatment group (n=80), mortality was 15.0% and 39.5% in control (n=81). The COVID stage progression was 65% less in treatment group.ConclusionSiddha regimen demonstrated that they can synergistically improve oxygenation status, enhance the recovery rate and reduce the mortality better as compared to only Standard of Care.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.